Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions. Beyond COVID-19, the company is developing vaccines targeting influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV) and Zika virus, as well as combination vaccines designed to protect against multiple respiratory pathogens. In addition to vaccines, Moderna is exploring mRNA therapeutics for oncology, rare diseases and cardiovascular conditions, leveraging partnerships with academic institutions and government agencies to accelerate development.
The company was co-founded by a team of scientists and backed by Flagship Pioneering. Stéphane Bancel joined as chief executive officer in 2011 and has overseen Moderna’s rapid growth from a research-stage enterprise to a globally recognized biopharmaceutical company. Under his leadership, Moderna established large-scale manufacturing capabilities and forged collaborations with public health bodies such as the Biomedical Advanced Research and Development Authority (BARDA) in the United States and the Coalition for Epidemic Preparedness Innovations (CEPI).
Moderna’s operations extend worldwide, with regional offices across North America, Europe and Asia-Pacific, and manufacturing facilities in the United States and Europe. The company continues to expand its global footprint through strategic alliances, technology transfer agreements and participation in international vaccine distribution initiatives. As it advances its mRNA platform, Moderna aims to build a diversified portfolio of products to address both emerging and longstanding public health challenges.